Home > Boards > US Listed > Medical - Drugs >

Provectus Biopharmaceuticals Inc. (PVCT)

Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, Ovidius, Southern Gal, buccaneer1961, TOB, David Fowler
Search This Board:
Last Post: 7/22/2014 1:37:34 PM - Followers: 161 - Board type: Free - Posts Today: 5

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.

PVCT on YouTube...


Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.

Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals

PVCT 6 months chart:

Technical analysis:

PVCT News:




PVCT insiders transactions:


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.


This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.

Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
Share Statistics
45.45 m
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PVCT News: Current Report Filing (8-k) 05/27/2014 03:45:39 PM
PVCT News: Current Report Filing (8-k) 05/23/2014 02:19:35 PM
PVCT News: Current Report Filing (8-k) 05/21/2014 03:32:59 PM
PVCT News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/20/2014 05:20:44 PM
PVCT News: Statement of Changes in Beneficial Ownership (4) 05/20/2014 06:08:15 AM
News News Alert: SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Provectus Biopharmaceuticals, Inc. to Conta... 07/22/2014 05:59:53 PM
#3564  Sticky Note Provectus SEC Filings... Gulfbreeze 05/01/14 12:10:06 AM
#3563  Sticky Note PLEASE STICKY THIS INFORMATION laxerpro22 04/30/14 11:21:55 PM
#6180   PVCT volume below average. TOB 07/22/14 01:37:34 PM
#6176   a tweet pacificnorthwest1 07/22/14 01:16:05 AM
#6175   OMG....descending Triangles !?!...Yikes 123tom 07/21/14 05:56:21 PM
#6173   Descending Triangles pacificnorthwest1 07/20/14 03:44:30 PM
#6172   http://en.m.wikipedia.org/wiki/Haybittle–Peto_boundary Here we see the rules for stoppage when vorlon1966 07/19/14 11:27:33 PM
#6171   It's called a stoppage rule. vorlon1966 07/19/14 11:03:03 PM
#6170   The articles I posted do not show up vorlon1966 07/19/14 10:35:33 PM
#6169   No no no vorlon1966 07/19/14 10:23:43 PM
#6168   "In all likelihood the bridging study and the jpaz70 07/19/14 08:26:23 PM
#6167   Enough with the personal attacks, we are voicing EODparty7 07/19/14 07:04:06 PM
#6166   Thanks Vorlon for sharing your knowledge regarding the Groscoe 07/19/14 05:56:44 PM
#6164   Why people worry.....expectations did not match reality, bashers vorlon1966 07/19/14 03:50:45 PM
#6163   No, I'm not saying that worry makes anyone tim779 07/19/14 03:12:07 PM
#6162   The Big Picture vorlon1966 07/19/14 01:46:38 PM
#6161   Exactly. The market doesn't care whether we believe tim779 07/19/14 10:31:37 AM
#6160   People can be nervous or completely indifferent. big orange 07/19/14 09:43:59 AM
#6158   I believe in the drug , I think EODparty7 07/18/14 10:31:22 PM
#6157   Constantly relating negative feelings to me is a Groscoe 07/18/14 10:19:13 PM
#6156   You could fool me......I haven't read one post Groscoe 07/18/14 10:16:50 PM
#6155   Well If its pessimism your looking for head Gulfbreeze 07/18/14 09:55:59 PM
#6154   Just tryin to be realistic .. I'm definitely EODparty7 07/18/14 08:21:00 PM
#6153   Every one of his posts carry the same Groscoe 07/18/14 01:30:06 PM
#6152   There's a lot to be said for watching kanox 07/18/14 12:29:36 PM
#6151   Let me give a shot at answering this.....and vorlon1966 07/18/14 12:28:02 PM
#6150   Who said I left?....lol vorlon1966 07/18/14 12:09:29 PM
#6149   Reports from 50th American Society of Clinical Oncology pacificnorthwest1 07/18/14 10:28:28 AM
#6148   Probably because not much is going on with snidely 07/18/14 08:10:02 AM
#6147   Why has Vorlon the hard core long left Ovidius 07/18/14 01:16:53 AM
#6146   What is hard for me to understand is Ovidius 07/18/14 01:06:01 AM
#6145   You were right 123tom.. Kudos for a great Lcrazylegs84 07/17/14 09:08:31 PM
#6144   I am man haha .. I'm pretty young EODparty7 07/17/14 08:52:49 PM
#6143   You always come off as nervous about this stock... Gulfbreeze 07/17/14 07:54:42 PM
#6142   My sentiment exactly.. I'm just hoping they can EODparty7 07/17/14 06:55:28 PM
#6141   i hate this stock. i hate Adam F. SJI88 07/17/14 06:31:59 PM
#6140   Ruff close.. Seems we are inching our way EODparty7 07/17/14 04:54:47 PM
#6139   got to love the transparency of so many Ovidius 07/16/14 11:40:57 PM
#6138   CTD Blog July 16 pacificnorthwest1 07/16/14 10:31:19 PM
#6137   Thanks, Gbert, I appreciate your thoughts . 123tom 07/16/14 03:41:42 PM
#6136   good points,G,.... 123tom 07/16/14 01:38:12 PM
#6135   Good assessment and I like your low numbers G Bert 07/16/14 09:49:53 AM
#6134   targets below if we see another downwave..... 123tom 07/16/14 03:25:18 AM
#6133   CTD Blog: Revisiting Cash On Hand (July pacificnorthwest1 07/16/14 12:01:42 AM
#6132   Thanks PacNW, very important link in 123tom 07/15/14 11:40:23 PM
#6131   Snidely, you could be right about that.... 123tom 07/15/14 11:39:18 PM
#6130   Tom, I hate to say it but looks snidely 07/15/14 07:26:14 PM
#6129   Four quick points on Yellen's biotech comment pacificnorthwest1 07/15/14 06:32:27 PM
#6128   The days of plunges is gone for PVCT. FortStCowboy 07/15/14 05:30:37 PM
#6127   So where would you place your stink bid,just 123tom 07/15/14 05:04:51 PM
#6126   Videos aside I really hope something happened soon EODparty7 07/15/14 04:43:10 PM
#6125   If PVCT doesn't do something....the video clips are 123tom 07/15/14 02:50:23 PM